Skip to main content
Clinical Trials/NCT01231880
NCT01231880
Completed
Phase 3

School-based Malaria Control: Impact of Intermittent Preventive Treatment on Malaria Morbidity and Cognitive Function in Ugandan School Children

Makerere University1 site in 1 country740 target enrollmentFebruary 2011

Overview

Phase
Phase 3
Intervention
Four monthly IPT with dihydroartemisinin Piperaquine (DP)
Conditions
Malaria
Sponsor
Makerere University
Enrollment
740
Locations
1
Primary Endpoint
Risk of Clinical Malaria
Status
Completed
Last Updated
12 years ago

Overview

Brief Summary

The investigators hypothesize that schoolchildren treated with IPT using DP over one year of follow-up will have a different risk of clinical malaria compared to those treated with placebo.

Registry
clinicaltrials.gov
Start Date
February 2011
End Date
September 2012
Last Updated
12 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Faculty of Medicine

Dr

Makerere University

Eligibility Criteria

Inclusion Criteria

  • Age ≥ 6 - 14 years
  • Pupils enrolled at participating school
  • Willingness of the parent/guardian to provide consent
  • Provision of assent by pupil (those above 8 years)

Exclusion Criteria

  • Known allergy or history of adverse reaction to study medications
  • Intention of changing of schools during the follow-up period
  • History (obtained from the parent/guardian) of any known serious chronic disease requiring frequent medical care

Arms & Interventions

Four monthly IPT

IPT give once a school term (every four months)

Intervention: Four monthly IPT with dihydroartemisinin Piperaquine (DP)

Monthly IPT

IPT given every month

Intervention: Monthly IPT using DP

Placebo

No active drug in the placebo

Intervention: Placebo given every month

Outcomes

Primary Outcomes

Risk of Clinical Malaria

Time Frame: 1 year

Fever(temperature greater or equal to 37.5 degrees centigrade or history of fever in past 24 hours) in presence of parasitemia.

Cognitive function tests

Time Frame: 1 year

Mean score in the cognitive function tests (Raven's Matrices test and Code transmission test)

Secondary Outcomes

  • Risk of parasitemia(1 year)
  • Risk of hospital admissions(1 year)
  • Risk of adverse events(1 year)
  • School performance(1 year)
  • Prevalence of anemia(1 year)

Study Sites (1)

Loading locations...

Similar Trials